The formulation of the GOP–PCA–FA nanocomposite shows that the folic acid-coated active targeting system has resulted in a significant reduction in cell cytotoxicity, and increased the potential of anti-cancer treatment due to the controlled sustained release of PCA compared to the GOP–PCA nanocomposite and pristine PCA drug. This evidence concerns the gene FLVCR1 and cancer.